Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

The 2025 Clinical Trial Supply West Coast conference will gather experts to discuss US trial operations in a shifting tariff landscape.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.